Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inder Kaul

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
The International Journal of Neuropsychopharmacology|March 8, 2025
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trialsJonathan M Meyer, Ken Kramer, Scott Vuocolo, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 21, 2013
Dysregulation of inflammatory and hemostatic markers in sepsis and suspected disseminated intravascular coagulationDebra Hoppensteadt, Kazuhisa Tsuruta, Joe Hirman, et al.
The Journal of Clinical Psychiatry|April 11, 2025
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT TrialsPaul P Yeung, Alan Breier, Haiyuan Zhu, et al.
Journal of the Neurological Sciences|January 2, 2021
Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label studyAmy Bullock, Inder Kaul, Sigui Li, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 28, 2013
Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulinDebra Hoppensteadt, Kazuhisa Tsuruta, Josephine Cunanan, et al.
Schizophrenia Research|January 8, 2026
Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5)Inder Kaul, Amy Claxton, Soumya Chaturvedi, et al.
The American Journal of Psychiatry|February 4, 2026
Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension TrialInder Kaul, Amy Claxton, Colin Sauder, et al.
Lancet (London, England)|December 17, 2023
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trialInder Kaul, Sharon Sawchak, Christoph U Correll, et al.
Schizophrenia Research|January 31, 2025
Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophreniaPhilip D Harvey, Inder Kaul, Soumya Chataverdi, et al.
Schizophrenia Research|April 22, 2026
Effects of Xanomeline and Trospium Chloride for Negative Symptoms Associated With Physical Activity in Younger and Older Adults with Schizophrenia: Results From a 52-Week, Open-label Clinical TrialPhilip D Harvey, Inder Kaul, Soumya Chataverdi, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
The International Journal of Neuropsychopharmacology|March 8, 2025
From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from clinical trialsJonathan M Meyer, Ken Kramer, Scott Vuocolo, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|November 21, 2013
Dysregulation of inflammatory and hemostatic markers in sepsis and suspected disseminated intravascular coagulationDebra Hoppensteadt, Kazuhisa Tsuruta, Joe Hirman, et al.
The Journal of Clinical Psychiatry|April 11, 2025
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT TrialsPaul P Yeung, Alan Breier, Haiyuan Zhu, et al.
Journal of the Neurological Sciences|January 2, 2021
Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label studyAmy Bullock, Inder Kaul, Sigui Li, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|June 28, 2013
Thrombin generation mediators and markers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulinDebra Hoppensteadt, Kazuhisa Tsuruta, Josephine Cunanan, et al.
Schizophrenia Research|January 8, 2026
Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5)Inder Kaul, Amy Claxton, Soumya Chaturvedi, et al.
The American Journal of Psychiatry|February 4, 2026
Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension TrialInder Kaul, Amy Claxton, Colin Sauder, et al.
Lancet (London, England)|December 17, 2023
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trialInder Kaul, Sharon Sawchak, Christoph U Correll, et al.
Schizophrenia Research|January 31, 2025
Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophreniaPhilip D Harvey, Inder Kaul, Soumya Chataverdi, et al.
Schizophrenia Research|April 22, 2026
Effects of Xanomeline and Trospium Chloride for Negative Symptoms Associated With Physical Activity in Younger and Older Adults with Schizophrenia: Results From a 52-Week, Open-label Clinical TrialPhilip D Harvey, Inder Kaul, Soumya Chataverdi, et al.
Pageof 3